BioCentury | Nov 23, 2020
Emerging Company Profile

SV Health-incubated Catamaran debuts with $42M to develop CAR NK pipeline

Catamaran debuted Monday with a $42 million series A round to advance a pipeline of allogeneic CAR NK cell therapies that seed investor SV Health hopes can “democratize access to cell therapy.”  SV’s Houman Ashrafian...
BioCentury | Nov 18, 2020
Emerging Company Profile

InterVenn: liquid biopsy diagnostics based on glycoproteins

InterVenn is tapping the glycoproteome for new markers for blood-based cancer diagnostics and using machine learning to accelerate the biomarker discovery process.  The company announced Monday that...
BioCentury | Nov 14, 2020
Emerging Company Profile

Metagenomi hunts for new gene editing systems with $65M series A

Metagenomi is systematizing the search for new gene editing tools by scouring the genomes of bacteria in ecological samples. The company emerged from stealth Thursday with a $65 million series A round...
BioCentury | Oct 3, 2020
Translation in Brief

A SARS-CoV-2 genome degrader; neutralizing influenza B mAbs; Fulcrum’s sickle cell therapy increases fetal hemoglobin and more

Matt Disney’s small molecule RNA degraders for COVID-19A Scripps Research team led by Expansion Therapeutics Inc. founder Matthew Disney published an ACS Central Science study describing a small molecule that binds a SARS-CoV-2 hairpin RNA structure that...
BioCentury | Oct 2, 2020
Deals

Genentech neoantigen deal gives Vaccibody runway to speed up infectious disease pipeline

Having licensed its neoantigen cancer vaccine to Genentech for $200 million in upfront and near-term payments, Norwegian biotech Vaccibody will use the proceeds to advance the infectious disease...
BioCentury | Sep 22, 2020
Deals

Grail chooses Illumina takeout over IPO, promising more future returns for shareholders

Rather than going public as planned, early cancer detection company Grail chose to be acquired by Illumina in a deal that will provide immediate returns to the outside investors that backed its spinout...
BioCentury | Sep 19, 2020
Product Development

Hexagon to scale up fungal metabolite discovery for new therapeutic compounds with $47M series A

With a focus on fungal infections and cancer, Hexagon is sourcing secondary metabolites from fungal genomes to develop small molecules against new protein targets.  Hexagon Bio Inc. announced...
BioCentury | Sep 15, 2020
Product Development

Lilly’s Olumiant adds to remdesivir benefit in NIH COVID-19 study

Data from NIAID’s ACTT-2 study mark Lilly’s rheumatoid arthritis drug as the first targeted immunomodulator to succeed in a randomized, controlled Phase III study in hospitalized COVID-19 patients, and support combining immunotherapies with Gilead’s remdesivir...
BioCentury | Sep 10, 2020
Emerging Company Profile

Generate: applying machine learning to protein design

Generate Biomedicines, the latest company to emerge from Flagship Pioneering, has a machine learning platform for creating new biologic therapies that should sidestep the trial and error process used to uncover most protein drugs. The...
BioCentury | Aug 15, 2020
Deals

Scipher tech could fatten Galapagos’ IBD pipeline

Galapagos’ deal with Scipher could fuel the Belgian biotech’s portfolio by uncovering first-in-class inflammatory bowel disease targets while its lead product moves through Phase III testing for two...
Items per page:
1 - 10 of 799
BioCentury | Nov 23, 2020
Emerging Company Profile

SV Health-incubated Catamaran debuts with $42M to develop CAR NK pipeline

Catamaran debuted Monday with a $42 million series A round to advance a pipeline of allogeneic CAR NK cell therapies that seed investor SV Health hopes can “democratize access to cell therapy.”  SV’s Houman Ashrafian...
BioCentury | Nov 18, 2020
Emerging Company Profile

InterVenn: liquid biopsy diagnostics based on glycoproteins

InterVenn is tapping the glycoproteome for new markers for blood-based cancer diagnostics and using machine learning to accelerate the biomarker discovery process.  The company announced Monday that...
BioCentury | Nov 14, 2020
Emerging Company Profile

Metagenomi hunts for new gene editing systems with $65M series A

Metagenomi is systematizing the search for new gene editing tools by scouring the genomes of bacteria in ecological samples. The company emerged from stealth Thursday with a $65 million series A round...
BioCentury | Oct 3, 2020
Translation in Brief

A SARS-CoV-2 genome degrader; neutralizing influenza B mAbs; Fulcrum’s sickle cell therapy increases fetal hemoglobin and more

Matt Disney’s small molecule RNA degraders for COVID-19A Scripps Research team led by Expansion Therapeutics Inc. founder Matthew Disney published an ACS Central Science study describing a small molecule that binds a SARS-CoV-2 hairpin RNA structure that...
BioCentury | Oct 2, 2020
Deals

Genentech neoantigen deal gives Vaccibody runway to speed up infectious disease pipeline

Having licensed its neoantigen cancer vaccine to Genentech for $200 million in upfront and near-term payments, Norwegian biotech Vaccibody will use the proceeds to advance the infectious disease...
BioCentury | Sep 22, 2020
Deals

Grail chooses Illumina takeout over IPO, promising more future returns for shareholders

Rather than going public as planned, early cancer detection company Grail chose to be acquired by Illumina in a deal that will provide immediate returns to the outside investors that backed its spinout...
BioCentury | Sep 19, 2020
Product Development

Hexagon to scale up fungal metabolite discovery for new therapeutic compounds with $47M series A

With a focus on fungal infections and cancer, Hexagon is sourcing secondary metabolites from fungal genomes to develop small molecules against new protein targets.  Hexagon Bio Inc. announced...
BioCentury | Sep 15, 2020
Product Development

Lilly’s Olumiant adds to remdesivir benefit in NIH COVID-19 study

Data from NIAID’s ACTT-2 study mark Lilly’s rheumatoid arthritis drug as the first targeted immunomodulator to succeed in a randomized, controlled Phase III study in hospitalized COVID-19 patients, and support combining immunotherapies with Gilead’s remdesivir...
BioCentury | Sep 10, 2020
Emerging Company Profile

Generate: applying machine learning to protein design

Generate Biomedicines, the latest company to emerge from Flagship Pioneering, has a machine learning platform for creating new biologic therapies that should sidestep the trial and error process used to uncover most protein drugs. The...
BioCentury | Aug 15, 2020
Deals

Scipher tech could fatten Galapagos’ IBD pipeline

Galapagos’ deal with Scipher could fuel the Belgian biotech’s portfolio by uncovering first-in-class inflammatory bowel disease targets while its lead product moves through Phase III testing for two...
Items per page:
1 - 10 of 799